Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: The Spanish Study Group experience

Clinical and Experimental Rheumatology

Volumn 26, Issue 5, 2008, Pages 854-859

  Peña Sagredo, José L ^a   Hernández, María V ^b   Fernandez Llanio, Nagore ^c   Giménez Ubeda, Eugenio ^d   Muñoz Fernandez, Santiago ^e   Ortiz, A ^f   Gonzalez Gay, Miguel A ^g   Fariñas, Maria Carmen ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Hospital Dr Pesec   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL XERAL CALDE   (Spain)

Author keywords

Listeria monocytogenes; Rheumatic disease; TNF alpha blockers

Indexed keywords

ADALIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOPHTHALMITIS; EUROPE; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; MENINGITIS; MORBIDITY; PERITONITIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; SEPSIS; SEPTICEMIA; SPAIN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; LISTERIA INFECTIONS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57249108546     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. LOCKSLEY RM, KILLEEN N, LENARDO MJ: The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104: 487-501.
2. IMPERATO AK, BINGHAM CO 3RD, ABRAMSON SB: Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S108-14.
3. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35-45. Erratum in: Arthritis Rheum 2003; 48: 855.
4. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
5. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
6. DIXON WG, WATSON K, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP: British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
7. GOMEZ-REINO JJ, CARMONA L, VALVERDE VR, MOLA EM, MONTERO MD; BIOBADASER GROUP: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
8. VALESINI G, MONTECUCCO C, CUTOLO M: Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 2006; 24: 413-23.
9. BIOBADASER SCIENTIFIC COMMITTEE: BIObADASER: Spanish registry of adverse events of biological therapies in rheumatic diseases. Rev Esp Reumatol 2002; 29: 292-9.
10. VALK H, JACQUET C, GOULET V et al.: Surveillance of Listeria Infections in Europe. Euro Surveill 2005; 10: 251 5.
11. CARMONA L, GONZALEZ-ALVARO I, BALSA A, BELMONTE MA, TENA X, SANMARTI R: Rheumatoid arthritis in Spain: Occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003; 62: 897-900
12. MCCAMBRIDGE MM, VOGELGESANG SA, OCKENHOUSE CF: Listeria monocytogenes infection in a patient treated with methotrexate for rheumatoid arthritis. J Rheumatol 1995; 22: 786-7.
13. BIEBER J, KAVANAUGH A: Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004; (Suppl. 35): S126-33.
14. Safety update on TNF-α antagonists: Infliximab and etanercept http://www.fda.gov/ohrms/dockets/ac/01briefing/ 3779b2-01-cbr-safety%20-revision2.pdf.p16
15. PAGLIANO P, ATTANASIO V, FUSCO U, MOHAMED DA, ROSSI M, FAELLA FS. Does etanercept monotherapy enhance the risk of Listeria monocytogenes infection? Ann Reum Dis 2003, 63: 462-3.
16. SLIFMAN NR, GERSHON SK, LEE JH, EDWARDS ET, BRAUN MM: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319-24.
17. BOWIE VL, SNELLA KA, GOPALACHAR AS, BHARADWAJ P: Listeria meningitis associated with infliximab. Ann Pharmacother 2004; 38: 58-61.
18. GLÜK T, LINDE HJ, SCHÖLMERICH J, MÜLLER-LANDER U, FIEHN C, BOHLAND P: Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: Report of two cases Arthritis Rheum 2002; 46: 2255-7.
19. JOOSTEN AA, VAN OLFFEN GH, HAGEMAN G: Meningitis due to Listeria monocytogenes as a complication of infliximab therapy. Ned Tijdschr Geneeskd 2003; 147:1470-2.
20. SCHETT G, HERAK P, GRANINGER W, SMOLEN JS, ARINGER M: Listeria-associated arthritis in a patient undergoing etanercept therapy: Case report and review of the literature. J Clin Microbiol 2005; 43: 2537-41.
21. NADARAJAH K, PRITCHARD C: Listeria monocytogenes septic arthritis in a patient treated with etanercept for rheumatoid arthritis. Clin Rheumatol 2005; 11: 120-2.
22. KESTEMAN T, YOMBI JC, GIGI J, DUREZ P: Listeria infections associated with infliximab: Case reports. Clin Rheumatol 2007; 26: 2173-5
23. SCHETT G, HERAK P, GRANINGER W, SMOLEN JS, ARINGER M: Listeria-associated arthritis in a patient undergoing etanercept therapy: Case report and review of the literature. J Clin Microbiol 2005; 43: 2537-41.
24. LA MONTAGNA G, VALENTINI G: Listeria monocytogenes meningitis in a patient receiving etanercept for Still's disease. Clin Exp Rheumatol 2005; 23: 121.
25. EDELSON BT, UNANUE ER: Immunity to Listeria infection. Curr Opin Immunol 2000; 425-31.
26. NAKANE A, MINAGAWA T, KATO K: Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 2563-9.
27. BETRIU C, FUENTEMILLA S, MÉNDEZ R, PICAZO JJ, GARCÍA-SÁNCHEZ J: Endophthalmitis caused by Listeria monocytogenes. J Clin Microbiol 2001; 39: 2742-4.
28. MENDEZ-HERNANDEZ C, GARCIA-FEIJOO J, GARCIA-SANCHEZ J: Lysteria monocytogenes-induced endogenous endophthalmitis: Bioultrasonic findings. Am J Opthalmol 2004 137: 579-81.
29. NOLLA-SALAS J, ANTÓ JM, ALMELA M, COLL P, GASSER I, PLASENCIA A: Incidence of listeriosis in Barcelona, Spain, in 1990. The Collaborative Study Group of Listeriosis of Barcelona. Eur J Clin Microbiol Infect Dis 1993; 12: 157-61.
30. GONZALEZ-JUANATEY C, LLORCA J, SANCHEZ-ANDRADE A, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA: Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006; 24: 309-12.
31. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.